Zevra Therapeutics Stock Beta
| ZVRA Stock | 9.51 0.00 0.00% |
Zevra Therapeutics fundamentals help investors to digest information that contributes to Zevra Therapeutics' financial success or failures. It also enables traders to predict the movement of Zevra Stock. The fundamental analysis module provides a way to measure Zevra Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zevra Therapeutics stock.
Zevra | Beta |
Zevra Therapeutics Company Beta Analysis
Zevra Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Zevra Therapeutics Beta | 1.93 |
Most of Zevra Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zevra Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zevra Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Zevra Therapeutics is extremely important. It helps to project a fair market value of Zevra Stock properly, considering its historical fundamentals such as Beta. Since Zevra Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zevra Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zevra Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Zevra Therapeutics has a Beta of 1.931. This is 124.53% higher than that of the Biotechnology sector and 38.92% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Zevra Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zevra Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zevra Therapeutics could also be used in its relative valuation, which is a method of valuing Zevra Therapeutics by comparing valuation metrics of similar companies.Zevra Therapeutics is currently under evaluation in beta category among its peers.
Zevra Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zevra Therapeutics from analyzing Zevra Therapeutics' financial statements. These drivers represent accounts that assess Zevra Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zevra Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 60.8M | 31.9M | 11.2M | 259.3M | 233.3M | 245.0M | |
| Enterprise Value | 143.4M | 95.6M | 87.6M | 148.5M | 133.7M | 87.9M |
Zevra Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zevra Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zevra Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zevra Therapeutics will likely underperform.
Zevra Fundamentals
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (7.39) % | ||||
| Current Valuation | 477.62 M | ||||
| Shares Outstanding | 53.38 M | ||||
| Shares Owned By Insiders | 6.61 % | ||||
| Shares Owned By Institutions | 54.46 % | ||||
| Number Of Shares Shorted | 4.11 M | ||||
| Price To Book | 7.27 X | ||||
| Price To Sales | 20.71 X | ||||
| Revenue | 27.46 M | ||||
| Gross Profit | 10.12 M | ||||
| EBITDA | (48.6 M) | ||||
| Net Income | (46.05 M) | ||||
| Total Debt | 43.77 M | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (33.53 M) | ||||
| Short Ratio | 6.66 X | ||||
| Earnings Per Share | (2.13) X | ||||
| Price To Earnings To Growth | 10.67 X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 65 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 507.07 M | ||||
| Total Asset | 172.33 M | ||||
| Retained Earnings | (399.78 M) | ||||
| Working Capital | 81.3 M | ||||
| Net Asset | 172.33 M |
About Zevra Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zevra Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zevra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zevra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out Zevra Therapeutics Piotroski F Score and Zevra Therapeutics Altman Z Score analysis. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.